Ipamorelin is a synthetic pentapeptide growth hormone secretagogue known for its remarkable selectivity. Among the GHRP (Growth Hormone Releasing Peptide) family, it stands out for stimulating growth hormone release while having minimal effects on other hormonal axes.
Research Applications
Research contexts include GH axis stimulation (selective, clean GH release), body composition studies, bone density research, recovery and tissue repair, and age-related GH decline models.
Dosage Information (Research Use)
Common research protocols: 100-300 mcg per administration, 1-3 times daily. Frequently paired 1:1 with CJC-1295 (Mod-GRF). Research use only.
Reconstitution & Handling
Standard BAC water reconstitution. Dissolves quickly and clearly.
Half-Life & Pharmacokinetics
Approximately 2 hours, supporting multiple daily administrations in pulsatile protocols.
Reported Observations in Literature
Generally well-tolerated in research. Mild hunger increase and transient head rush reported. Notably lacks the significant cortisol and prolactin elevation seen with GHRP-6 and GHRP-2.
Key Research References
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998
- Johansen PB, et al. “Ipamorelin: a new growth-hormone-releasing peptide.” J Endocrinol. 1999